Biodexa regain compliance with nasdaq minimum bid price requirement

Biodexa pharmaceuticals plc (“biodexa” or the “company”) biodexa regain compliance with nasdaq minimum bid price requirement biodexa pharmaceuticals plc (nasdaq: bdrx), a clinical-stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain, announced today that, on july 20, 2023, it received a notification from the nasdaq stock market llc (“nasdaq”) confirming the company has cured the previously disclosed bid price deficiency, and that the company is in compliance with all applicable listing standards. the company's securities will continue to be listed and traded on nasdaq and the previously announced hearing with the nasdaq hearing panel is cancelled.
BDRX Ratings Summary
BDRX Quant Ranking